Bio-Rad Laboratories, Inc. is among the top undervalued healthcare stocks, launching new digital PCR systems in 2025. The company expanded its capabilities with the acquisition of Stilla Technologies, offering over 400,000 assays for oncology, infectious disease, and genetic analysis. Bio-Rad also released ddPCR kits for accurate AAV vector measurement and launched new purification tools and kits for antibody conjugation.

In addition to its product launches, Bio-Rad Laboratories, Inc. remained active in global industry events throughout 2025, showcasing its expanding technology portfolio for clinical and research applications. The company offered workshops on diagnostic innovation, highlighting its commitment to advancing healthcare solutions.

While Google (GOOGL) shows investment potential, certain AI stocks offer greater upside and lower downside risk. For an undervalued AI stock with growth potential from Trump-era tariffs and onshoring trends, check out the best short-term AI stock in a free report. Explore more insights on Dow stocks and unstoppable stocks for potential investment opportunities.

Read more at Yahoo Finance: Bio-Rad Laboratories, Inc. (BIO) Launches New Digital PCR Systems in 2025